When to resume antitumor therapy in COVID-19-infected tumor patients: a retrospective, real-world study.

ABSTRACT:

Purpose

To study the safety of resuming antitumor therapy in tumor patients infected with COVID-19.

Methods

We collected the clinical information of patients with tumors who were infected with COVID-19 and resume antitumor therapy between December 2022 and June 2023. Information about antitumor therapy, COVID-19-related symptoms, laboratory tests, antitumor therapy-related adverse events (AEs), and re-infection with COVID-19 were recorded. Primary endpoints included the incidence of AEs and re-infection of COVID-19. The secondary endpoints included the incidence and duration of COVID-19 related symptoms.

Results

The most common COVID-19 symptoms were fever (39.5%), cough (37.2%), and fatigue (44.2%). Most patients' symptoms lasted no more than a week Two patients were

SUBMITTER: Pan X 

PROVIDER: S-EPMC11897109 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature